Neuren Pharmaceuticals AGM Chair Address & CEO Presentation
Key points
- Neuren Pharmaceuticals is focused on developing treatments for rare neurological disabilities
- DAYBUE sales grew by 12% in 2025, reaching $391 million
- DAYBUE STIX launched in Q1 2026, with over 250 prescriptions
- Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome (PMS) is underway
- Neuren is exploring capital management options including share buybacks and dividends
Full summary
Neuren Pharmaceuticals Ltd. remains focused on developing treatments for rare neurological disabilities. The company reported a strong financial and strategic position, with DAYBUE sales growing by 12% in 2025 to reach $391 million. DAYBUE STIX, a new powder formulation, launched in Q1 2026, with over 250 prescriptions. The Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome (PMS) is underway, with 7 trial sites activated and enrolling. Neuren is exploring capital management options including share buybacks and dividends.
Guidance
Neuren expects full year 2026 DAYBUE royalty income of $50-54 million, or approximately A$70-77 million.
Outlook
Neuren anticipates meaningful growth potential for DAYBUE in the United States and other markets, with further progress expected in Japan and Europe.
Summary generated by a large language model. Please interpret with care.